Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obeticholic acid deuterated - Suzhou Zelgen Biopharmaceuticals

Next Previous
Drug Profile

Obeticholic acid deuterated - Suzhou Zelgen Biopharmaceuticals

Alternative Names: Obeticholic acid magnesium tablets; ZG 5216

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Zelgen Biopharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antihypertensives; Cholic acids; Cyclopentanes; Gallstone therapies; Hepatoprotectants; Obesity therapies; Organic deuterium compounds; Pentanoic acids; Phenanthrenes; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Primary biliary cirrhosis
  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 09 Jun 2023 Chemical structure information added
  • 15 Dec 2022 Discontinued - Preclinical for Non-alcoholic steatohepatitis in China (unspecified route) before December 2022 (Suzhou Zelgen Biopharmaceuticals pipeline, December 2022)
  • 15 Dec 2022 Phase-I/II clinical trials in Primary biliary cirrhosis in China (PO) before December 2022 (Suzhou Zelgen Biopharmaceuticals pipeline, December 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top